STOCK TITAN

Aadi Bioscience, Inc. - AADI STOCK NEWS

Welcome to our dedicated page for Aadi Bioscience news (Ticker: AADI), a resource for investors and traders seeking the latest updates and insights on Aadi Bioscience stock.

Aadi Bioscience, Inc. (NASDAQ: AADI) is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway. The company's lead asset, FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension), is an mTOR inhibitor targeting cancers driven by genetic alterations in mTOR pathway genes. Aadi is committed to bringing transformational therapies to cancer patients with mTOR pathway driver alterations such as those in the TSC1 or TSC2 genes.

Aadi Bioscience has received FDA approval for FYARRO® for the treatment of adult patients with locally advanced unresectable or metastatic malignant perivascular epithelioid cell tumor (PEComa). FYARRO® is designed to improve delivery, stability, solubility, and targeting compared to traditional mTOR inhibitors and is being evaluated in various clinical trials. The company's innovative approach combines nanoparticle albumin-bound (nab) technology with the potent mTOR inhibitor, sirolimus.

The company's clinical pipeline includes the Phase 2 PRECISION1 trial, a tumor-agnostic registration-intended study exploring nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. The trial is expected to complete enrollment by the end of 2024, with interim analysis anticipated in Q3 2024.

In addition to PRECISION1, Aadi is conducting two other Phase 2 trials: one in advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole, and another in neuroendocrine tumors (NETs). Endometrial cancer is a common type of gynecologic cancer, and nab-sirolimus has shown promise in combination therapies for these difficult-to-treat cancers.

Financially, Aadi's Q1 2024 revenue from FYARRO® sales reached $5.4 million, reflecting a strong market presence as the preferred treatment for malignant PEComa. The company's robust financial position, with $88.3 million in cash and short-term investments as of March 2024, is expected to fund operations into Q4 2025.

Headquartered in Los Angeles, Aadi Bioscience is led by a team of industry veterans with extensive experience in developing and commercializing blockbuster oncology products. The company's mission is to unlock the full potential of mTOR inhibition and bring hope to patients with genetically-defined cancers.

Rhea-AI Summary

Aadi Bioscience, Inc. reported first quarter 2022 financial results, highlighting net product sales of $2.3 million from the launch of FYARRO in February.

The company emphasizes strong demand and favorable physician awareness. Operating expenses surged to $16.1 million, with a net loss of $13.9 million, compared to $5.5 million in Q1 2021. Aadi initiated dosing in the PRECISION 1 trial, targeting TSC1/TSC2 gene alterations, and expects initial clinical data in 2023. Aadi anticipates cash reserves will fund operations into 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.33%
Tags
-
Rhea-AI Summary

Aadi Bioscience has announced collaborations with leading next-generation sequencing (NGS) companies, including Foundation Medicine and Tempus, to enhance enrollment in its PRECISION 1 trial. This Phase 2 registrational trial focuses on patients with advanced cancer exhibiting inactivating alterations in the TSC1 and TSC2 genes, with a projected US incidence of 12,000 patients. The partnerships aim to improve patient identification and enrollment speed for the trial, which evaluates nab-sirolimus. Preliminary data from the trial is expected in the first half of the following year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.81%
Tags
none
-
Rhea-AI Summary

Aadi Bioscience, Inc. (Nasdaq: AADI) announced the approval of a permanent J-code (J9331) for its drug FYARRO™ effective July 1, 2022. This J-code improves the reimbursement process for FYARRO, which treats adult patients with malignant perivascular epithelioid cell tumors (PEComa). The standardization will apply across Medicare and private insurance, facilitating claims submissions. FYARRO is the first approved treatment for PEComa and is now included in the NCCN Clinical Practice Guidelines as a preferred regimen. Aadi emphasized the significance of this milestone for patient access and commercial rollout.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.98%
Tags
none
Rhea-AI Summary

Aadi Bioscience (Nasdaq: AADI) will report its Q1 2022 results on May 12, 2022, before the market opens. Following this, a conference call will be held at 8:30 am EDT to discuss the results and provide a corporate update. Aadi focuses on precision therapies for cancers related to mTOR pathway gene alterations. The company’s FYARRO™ has received FDA approval for treating a rare tumor and is now commercially available. Aadi is also advancing its clinical pipeline with the launch of the PRECISION 1 trial targeting specific solid tumors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.38%
Tags
-
Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical company focusing on precision therapies for genetically-defined cancers, will participate in the Jefferies 'Biotech on the Bay' Summit on April 26-27, 2022, in Miami, FL. CEO Neil Desai and the executive team will be available for one-on-one meetings. The company aims to provide transformational therapies for cancer patients with mTOR pathway alterations. Aadi's drug FYARRO received FDA approval in November 2021 and was commercially launched in February 2022, targeting advanced perivascular epithelioid cell tumors. Aadi has also initiated a registrational trial, PRECISION 1.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.81%
Tags
conferences
-
Rhea-AI Summary

Aadi Bioscience announced a study estimating that by 2030, approximately 12,000 advanced cancer patients in the U.S. will have definite TSC1 or TSC2 mutations. The study, presented at the AACR Annual Meeting, evaluated cancer data from over 30 solid tumors. It found TSC1 alterations most common in bladder, kidney, and lung cancers, while TSC2 was prevalent in hepatobiliary, ovarian, and soft tissue sarcomas. Neil Desai, CEO of Aadi, mentioned the company's ongoing PRECISION 1 trial on nab-sirolimus targeting these mutations, with preliminary data expected next year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.11%
Tags
none
Rhea-AI Summary

Aadi Bioscience (Nasdaq: AADI) has received FDA Fast Track designation for nab-sirolimus, aimed at treating adult and adolescent patients with Tuberous Sclerosis Complex (TSC1 and TSC2) alterations. The company has initiated the PRECISION 1 Phase 2 trial, targeting approximately 120 patients with solid tumors having these genetic mutations. Preliminary results are anticipated in the first half of 2023. This designation aims to expedite the drug's development for patients lacking approved treatment options, potentially impacting over 10,000 advanced cancer patients annually.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
-
Rhea-AI Summary

Aadi Bioscience, Inc. (AADI) reported its financial results for Q4 and the full year of 2021, ending with $149.0 million in cash. The company launched FYARRO, the only FDA-approved treatment for malignant PEComa, added to NCCN Guidelines as the preferred therapy. The PRECISION 1 trial for nab-sirolimus targeting TSC1 and TSC2 alterations is now open for enrollment. However, Q4 operating expenses rose to $16.9 million, and the net loss for FY 2021 reached $110.7 million, significantly impacted by a $74.2 million impairment charge.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.4%
Tags
-
Rhea-AI Summary

Aadi Bioscience, a biopharmaceutical company focused on precision therapies for genetically-defined cancers, announced CEO Neil Desai will participate in a panel discussion on Tumor-Agnostic Development at Cowen's 42nd Annual Health Care Conference, held virtually from March 7-9, 2022. The discussion is scheduled for March 8 at 12:50 PM EST. Aadi's FYARRO, recently FDA-approved for specific cancer treatments, showcases the company's commitment to innovative therapies targeting mTOR pathway alterations. A replay of the panel will be accessible on Aadi's website for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.35%
Tags
conferences
Rhea-AI Summary

Aadi Bioscience has launched FYARRO™, the first FDA-approved treatment for malignant PEComa, a rare cancer. Recently included in the NCCN Guidelines as the only preferred mTOR inhibitor for this cancer, FYARRO offers hope for patients with previously no specific treatment options. The company announces the opening of the PRECISION-1 study, targeting tumor types with TSC1 or TSC2 alterations. Aadi also introduced Aadi Assist, a patient support program to facilitate access to FYARRO.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.86%
Tags
none

FAQ

What is the current stock price of Aadi Bioscience (AADI)?

The current stock price of Aadi Bioscience (AADI) is $2.28 as of November 21, 2024.

What is the market cap of Aadi Bioscience (AADI)?

The market cap of Aadi Bioscience (AADI) is approximately 58.2M.

What is Aadi Bioscience, Inc.?

Aadi Bioscience, Inc. is a commercial-stage precision oncology company focused on the development and commercialization of therapies for cancers with alterations in the mTOR pathway.

What is FYARRO®?

FYARRO® (sirolimus albumin-bound nanoparticles for injectable suspension) is an mTOR inhibitor developed by Aadi Bioscience for treating cancers driven by genetic alterations in mTOR pathway genes.

What are the key clinical trials of Aadi Bioscience?

Aadi Bioscience's key clinical trials include the Phase 2 PRECISION1 trial for solid tumors with TSC1 or TSC2 inactivating alterations, a Phase 2 trial in advanced or recurrent endometrioid-type endometrial cancer (EEC) in combination with letrozole, and a Phase 2 trial in neuroendocrine tumors (NETs).

What financial results did Aadi Bioscience achieve in Q1 2024?

In Q1 2024, Aadi Bioscience achieved $5.4 million in revenue from FYARRO® sales. The company had $88.3 million in cash and short-term investments as of March 2024.

What is the significance of the mTOR pathway in cancer treatment?

The mTOR pathway is a key regulator of cell growth and cancer progression. Alterations in this pathway can lead to various cancers. Aadi Bioscience focuses on developing therapies targeting these alterations to treat genetically-defined cancers.

Where is Aadi Bioscience headquartered?

Aadi Bioscience is headquartered in Los Angeles, California.

Who leads Aadi Bioscience?

Aadi Bioscience is led by a team of industry veterans with extensive experience in developing and commercializing blockbuster oncology products.

What are the upcoming milestones for Aadi Bioscience?

Upcoming milestones for Aadi Bioscience include the two-thirds interim analysis of the PRECISION1 trial in Q3 2024, full enrollment in the trial by the end of 2024, and ongoing enrollment in Phase 2 trials for EEC and NETs.

What are the potential benefits of nab-sirolimus?

Nab-sirolimus combines nanoparticle albumin-bound technology with sirolimus to improve drug delivery, stability, solubility, and targeting, potentially overcoming limitations of traditional mTOR inhibitors.

What is the mission of Aadi Bioscience?

Aadi Bioscience's mission is to unlock the full potential of mTOR inhibition and bring transformational therapies to cancer patients with genetically-defined cancers.

Aadi Bioscience, Inc.

Nasdaq:AADI

AADI Rankings

AADI Stock Data

58.17M
22.17M
9.96%
49.17%
1.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PACIFIC PALISADES